- Respiratory level tracking with visual biofeedback for consistent breath-hold level with potential application in image-guided interventions
- Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction
- The 2018 correlative microscopy techniques roadmap
- Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer
- Enhanced cognitive behavioural therapy for patients with eating disorders: A systematic review
- Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge
- Association Between Subjective Tinnitus and Cervical Spine or Temporomandibular Disorders: A Systematic Review
- Fish Intake, Circulating Mercury and Mortality in Renal Transplant Recipients
- Hatha yoga for acute, chronic and/or treatment-resistant mood and anxiety disorders: A systematic review and meta-analysis
- Reliability and predictive validity of the Standardized Infant NeuroDevelopmental Assessment neurological scale
Most Used Journals
Identification of 6-benzyloxysalicylates as a novel class of inhibitors of 15-lipoxygenase-1.
Eur J Med Chem. 2015 Mar 5;94:265-275
Authors: Eleftheriadis N, Thee S, Te Biesebeek J, van der Wouden P, Baas BJ, Dekker FJ
Lipoxygenases metabolize polyunsaturated fatty acids into signalling molecules such as leukotrienes and lipoxins. 15-lipoxygenase-1 (15-LOX-1) is an important mammalian lipoxygenase and plays a crucial regulatory role in several respiratory diseases such as asthma, COPD and chronic bronchitis. Novel potent and selective inhibitors of 15-LOX-1 are required to explore the role of this enzyme in drug discovery. In this study we describe structure activity relationships for 6-benzyloxysalicylates as inhibitors of human 15-LOX-1. Kinetic analysis suggests competitive inhibition and the binding model of these compounds can be rationalized using molecular modelling studies. The most potent derivative 37a shows a Ki value of 1.7 μM. These structure activity relationships provide a basis to design improved inhibitors and to explore 15-LOX-1 as a drug target.
PMID: 25771032 [PubMed – as supplied by publisher]